{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:26:48Z","timestamp":1648740408184},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00393-018-0488-4","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T04:16:50Z","timestamp":1528777010000},"page":"493-507","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interpretation des Tuberkulose- und Hepatitisscreenings vor immunsuppressiver Therapie"],"prefix":"10.1007","volume":"77","author":[{"given":"B.","family":"Ehrenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"key":"488_CR1","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a\u00a0tumor necrosis factor alpha-neutralizing agent. N\u00a0Engl J Med 345:1098\u20131104","journal-title":"N Engl J Med"},{"key":"488_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00393-009-0475-x","volume":"68","author":"R Diel","year":"2009","unstructured":"Diel R, Hauer B, Loddenkemper R et al (2009) Empfehlungen f\u00fcr das Tuberkulose-Screening vor Gabe von TNF-alpha-Inhibitoren bei rheumatischen Erkrankungen. Z\u00a0Rheumatol 68:411\u2013416","journal-title":"Z Rheumatol"},{"key":"488_CR3","unstructured":"Fachinformations-Infoservice. \n                    https:\/\/www.fachinfo.de\/suche\n                    \n                  , Zugegriffen: 3. Jan. 2018"},{"key":"488_CR4","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1136\/annrheumdis-2011-200941","volume":"71","author":"S Kleinert","year":"2012","unstructured":"Kleinert S, Tony HP, Krueger K et al (2012) Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-gamma release assays under real-life conditions. Ann Rheum Dis 71:1791\u20131795","journal-title":"Ann Rheum Dis"},{"key":"488_CR5","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-115427","author":"S Blaas","year":"2017","unstructured":"Blaas S (2017) Tuberkulose. Dtsch Med Wochenschr. \n                    https:\/\/doi.org\/10.1055\/s-0043-115427","journal-title":"Dtsch Med Wochenschr"},{"key":"488_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1055\/s-0043-105954","volume":"71","author":"T Schaberg","year":"2017","unstructured":"Schaberg T, Bauer T, Brinkmann F et al (2017) S2k-Leitlinie: Tuberkulose im Erwachsenenalter. Pneumologie 71:325\u2013397","journal-title":"Pneumologie"},{"key":"488_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/thoraxjnl-2015-207811","volume":"71","author":"SH Wong","year":"2016","unstructured":"Wong SH, Gao Q, Tsoi KK et al (2016) Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis screening in patients with autoimmune diseases: a\u00a0systematic review and meta-analysis. Thorax 71:64\u201372","journal-title":"Thorax"},{"key":"488_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10067-016-3462-z","volume":"36","author":"G Cuomo","year":"2017","unstructured":"Cuomo G, D\u2019abrosca V, Iacono D et\u00a0al (2017) The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis. Clin Rheumatol 36:457\u2013461","journal-title":"Clin Rheumatol"},{"key":"488_CR9","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1136\/annrheumdis-2014-205376","volume":"74","author":"C Hatzara","year":"2015","unstructured":"Hatzara C, Hadziyannis E, Kandili A et al (2015) Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis 74:1848\u20131853","journal-title":"Ann Rheum Dis"},{"key":"488_CR10","first-page":"498","volume":"12","author":"D Menzies","year":"2008","unstructured":"Menzies D, Gardiner G, Farhat M et al (2008) Thinking in three dimensions: a\u00a0web-based algorithm to aid the interpretation of tuberculin skin test results. Int J Tuberc Lung Dis 12:498\u2013505","journal-title":"Int J Tuberc Lung Dis"},{"key":"488_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522\u2013528","journal-title":"Ann Rheum Dis"},{"key":"488_CR12","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60:1884\u20131894","journal-title":"Arthritis Rheum"},{"key":"488_CR13","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/art.22768","volume":"57","author":"JJ Gomez-Reino","year":"2007","unstructured":"Gomez-Reino JJ, Carmona L, Descalzo AM et al (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57:756\u2013761","journal-title":"Arthritis Rheum"},{"key":"488_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","volume":"14","author":"F Cantini","year":"2015","unstructured":"Cantini F, Nannini C, Niccoli L et\u00a0al (2015) Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 14:503\u2013509","journal-title":"Autoimmun Rev"},{"key":"488_CR15","doi-asserted-by":"publisher","first-page":"8909834","DOI":"10.1155\/2017\/8909834","volume":"2017","author":"F Cantini","year":"2017","unstructured":"Cantini F, Nannini C, Niccoli L et al (2017) Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm 2017:8909834","journal-title":"Mediators Inflamm."},{"key":"488_CR16","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s00393-012-1038-0","volume":"71","author":"K Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger K, Wollenhaupt J, Albrecht K et al (2012) S1-Leitlinie der DGRh zur sequenziellen medikamentosen Therapie der rheumatoiden Arthritis 2012. Adaptierte EULAR-Empfehlungen und aktualisierter Therapiealgorithmus. Z\u00a0Rheumatol 71:592\u2013603","journal-title":"Z Rheumatol"},{"key":"488_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/thoraxjnl-2014-206470","volume":"70","author":"SK Brode","year":"2015","unstructured":"Brode SK, Jamieson FB, Ng R et al (2015) Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax 70:677\u2013682","journal-title":"Thorax"},{"key":"488_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1055\/s-0043-114048","volume":"143","author":"M Cornberg","year":"2018","unstructured":"Cornberg M (2018) Hepatitis B \u2013 Ein Ausblick auf aktualisierte Leitlinien. Dtsch Med Wochenschr 143:183\u2013188","journal-title":"Dtsch Med Wochenschr"},{"key":"488_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00103-013-1673-x","volume":"56","author":"C Poethko-Muller","year":"2013","unstructured":"Poethko-Muller C, Zimmermann R, Hamouda O et al (2013) Die Seroepidemiologie der Hepatitis A, B und C in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56:707\u2013715","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"488_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1055\/s-0031-1273462","volume":"49","author":"M Cornberg","year":"2011","unstructured":"Cornberg M, Protzer U, Petersen J et al (2011) Aktualisierung der S 3\u2011Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Z\u00a0Gastroenterol 49:871\u2013930","journal-title":"Z Gastroenterol"},{"key":"488_CR21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver, Electronic Address EEE, European Association for the Study of The L (2017) EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J\u00a0Hepatol 67:370\u2013398","journal-title":"J Hepatol"},{"key":"488_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT (2015) American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:221\u2013244.e3","journal-title":"Gastroenterology"},{"key":"488_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/1756-185X.13010","volume":"20","author":"LF Chen","year":"2017","unstructured":"Chen LF, Mo YQ, Jing J et al (2017) Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a\u00a0prospective clinical observation. Int J Rheum Dis 20:859\u2013869","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"488_CR24","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","volume":"77","author":"YM Chen","year":"2017","unstructured":"Chen YM, Huang WN, Wu YD et al (2017) Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a\u00a0real-world study. Ann Rheum Dis 77(5):780","journal-title":"Ann Rheum Dis"},{"key":"488_CR25","first-page":"831","volume":"35","author":"YC Tien","year":"2017","unstructured":"Tien YC, Yen HH, Chiu YM (2017) Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis. Clin Exp Rheumatol 35:831\u2013836","journal-title":"Clin Exp Rheumatol"},{"key":"488_CR26","first-page":"566","volume":"215","author":"MH Chen","year":"2017","unstructured":"Chen MH, Chen MH, Liu CY et\u00a0al (2017) Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J\u00a0Infect Dis 215:566\u2013573","journal-title":"J Infect Dis"},{"key":"488_CR27","first-page":"320","volume":"31","author":"H Ming-Xu","year":"2015","unstructured":"Ming-Xu H, Chen M, Cai Y et al (2015) Clinical outcomes of low-dose leflunomide for rheumatoid arthritis complicated with Hepatitis B virus carriage and safety observation. Pak J Med Sci 31:320\u2013324","journal-title":"Pak J Med Sci"},{"issue":"Suppl 4","key":"488_CR28","doi-asserted-by":"publisher","first-page":"S306","DOI":"10.1093\/cid\/ciw043","volume":"62","author":"SA Gonzalez","year":"2016","unstructured":"Gonzalez SA, Perrillo RP (2016) Hepatitis B virus reactivation in the setting of cancer chemotherapy and other immunosuppressive drug therapy. Clin Infect Dis 62(Suppl 4):S306\u2013S313","journal-title":"Clin Infect Dis"},{"key":"488_CR29","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2016-209973","volume":"76","author":"W Fukuda","year":"2017","unstructured":"Fukuda W, Hanyu T, Katayama M et\u00a0al (2017) Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a\u00a0multicentre, prospective, observational study in Japan. Ann Rheum Dis 76:1051\u20131056","journal-title":"Ann Rheum Dis"},{"key":"488_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","volume":"131","author":"CK Hui","year":"2006","unstructured":"Hui CK, Cheung WW, Zhang HY et al (2006) Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131:59\u201368","journal-title":"Gastroenterology"},{"key":"488_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","volume":"27","author":"W Yeo","year":"2009","unstructured":"Yeo W, Chan TC, Leung NW et\u00a0al (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J\u00a0Clin Oncol 27:605\u2013611","journal-title":"J Clin Oncol"},{"key":"488_CR32","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1002\/cncr.25253","volume":"116","author":"K Matsue","year":"2010","unstructured":"Matsue K, Kimura S, Takanashi Y et al (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B\u2011cell lymphoma. Cancer 116:4769\u20134776","journal-title":"Cancer"},{"key":"488_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","volume":"48","author":"HH Thein","year":"2008","unstructured":"Thein HH, Yi Q, Dore GJ et al (2008) Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a\u00a0meta-analysis and meta-regression. Hepatology 48:418\u2013431","journal-title":"Hepatology"},{"key":"488_CR34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.130658","volume":"41","author":"F Iannone","year":"2014","unstructured":"Iannone F, La Montagna G, Bagnato G et\u00a0al (2014) Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a\u00a0multicenter randomized clinical trial. J\u00a0Rheumatol 41:286\u2013292","journal-title":"J Rheumatol"},{"key":"488_CR35","volume-title":"S3-Leitlinie: \u201eProphylaxe, Diagnostik und Therapie der Hepatitis-C- Virus(HCV)-Infektion\u201c AWMF-Register-Nr.: 021\/012","author":"C Sarrazin","year":"2017","unstructured":"Sarrazin C, Zimmermann T, Berg T et al (2017) S3-Leitlinie: \u201eProphylaxe, Diagnostik und Therapie der Hepatitis-C- Virus(HCV)-Infektion\u201c AWMF-Register-Nr.: 021\/012. \n                    https:\/\/www.dgvs.de\/wp-content\/uploads\/2018\/02\/S3-Leitlinie-Hepatitis-C-ZfG-15.02.2018.pdf\n                    \n                  . Zugegriffen: 25. Febr. 2018"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-018-0488-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0488-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-018-0488-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T19:14:56Z","timestamp":1560280496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-018-0488-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1007\/s00393-018-0488-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,12]]},"assertion":[{"value":"12 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Ehrenstein gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine vom Autor durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}